Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02536833
Recruitment Status : Completed
First Posted : September 1, 2015
Results First Posted : September 16, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Samumed LLC

Tracking Information
First Submitted Date  ICMJE August 28, 2015
First Posted Date  ICMJE September 1, 2015
Results First Submitted Date  ICMJE July 23, 2020
Results First Posted Date  ICMJE September 16, 2020
Last Update Posted Date September 16, 2020
Actual Study Start Date  ICMJE September 9, 2015
Actual Primary Completion Date April 20, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 26, 2020)
Change From Baseline Osteoarthritis (OA) Pain in the Target Knee [ Time Frame: Baseline and Week 13 ]
Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.
Original Primary Outcome Measures  ICMJE
 (submitted: August 28, 2015)
  • Change from baseline OA pain in the target knee [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of patients with OA of the knee and hip, including pain, stiffness, and physical functioning of the joints.
  • Change from baseline OA function in the target knee [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA function in the target knee as assessed by the WOMAC function subscore at Week 13
  • Change from baseline OA disease activity assessed by the patient [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 26, 2020)
  • Change From Baseline OA Pain in the Target Knee [ Time Frame: Baseline and Week 26 ]
    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.
  • Change From Baseline OA Function in the Target Knee [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.
  • Change From Baseline OA Function in the Target Knee [ Time Frame: Baseline and Week 26 ]
    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.
  • Change From Baseline OA Disease Activity as Assessed by the Patient [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.
  • Change From Baseline OA Disease Activity as Assessed by the Patient [ Time Frame: Baseline and Week 26 ]
    Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 26. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by "Very Well" on the left (scored as 0) and "Very Poorly" on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.
  • Change From Baseline in Medial Joint Space Width of Target Knee [ Time Frame: Baseline and Week 26 ]
    Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 26.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 28, 2015)
  • Change from baseline in WOMAC total score for the target knee [ Time Frame: Baseline and Weeks 4, 13, 26, 39 and 52 ]
    Change from baseline in WOMAC total score for the target knee at Weeks 4, 13, 26, 39 and 52
  • Change From Baseline OA Pain in the Target Knee [ Time Frame: Baseline and Weeks 4, 26, 39 and 52 ]
    Change from baseline OA pain in the target knee as assessed by the WOMAC pain subscore at Weeks 4, 26, 39 and 52
  • Change From Baseline OA Function in the Target Knee [ Time Frame: Baseline and Weeks 4, 26, 39 and 52 ]
    Change from baseline OA function in the target knee as assessed by the WOMAC function subscore at Weeks 4, 26, 39 and 52
  • Change From Baseline OA Disease Activity as Assessed by the Patient [ Time Frame: Baseline and Weeks 4, 26, 39 and 52 ]
    Change from baseline OA disease activity as assessed by the Patient Global Assessment at Weeks 4, 26, 39 and 52
  • Change from baseline in joint space width (JSW) of target knee [ Time Frame: Baseline and Weeks 26 and 52 ]
    Change from baseline in JSW as documented by X-ray of the target knee at Weeks 26 and 52
  • Percentage of Outcome Measures in Rheumatology Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) "strict" responders [ Time Frame: Baseline and Weeks 13, 26 and 52 ]
    Percentage of OMERACT-OARSI "strict" responders at Weeks 13, 26, and 52. OMERACT-OARSI "strict" responders are defined as subjects experiencing a ≥50% improvement in pain or function with a corresponding ≥20 point change (using 100 point scale)
  • Change from baseline health-related quality of life (HRQOL) [ Time Frame: Baseline and Weeks 4, 13, 26, 39 and 52 ]
    Change from baseline HRQOL as assessed by the 36-Item Short Form Health Survey (SF-36) at Weeks 4, 13, 26, 39 and 52
  • Change from baseline OA disease activity as assessed by the physician [ Time Frame: Baseline and Weeks 4, 13, 26, 39 and 52 ]
    Change from baseline OA disease activity as assessed by the Physician Global Assessment at Weeks 4, 13, 26, 39 and 52
Current Other Pre-specified Outcome Measures
 (submitted: August 26, 2020)
  • Change From Baseline OA Pain in the Target Knee [ Time Frame: Baseline and Week 52 ]
    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.
  • Change From Baseline OA Function in the Target Knee [ Time Frame: Baseline and Week 52 ]
    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.
  • Change From Baseline in Medial Joint Space Width of Target Knee [ Time Frame: Baseline and Week 52 ]
    Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.
  • Change From Baseline OA Pain in the Target Knee [Unilateral Symptomatic OA] [ Time Frame: Baseline and Week 52 ]
    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.
  • Change From Baseline OA Function in the Target Knee [Unilateral Symptomatic OA] [ Time Frame: Baseline and Week 52 ]
    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.
  • Change From Baseline in Medial Joint Space Width of Target Knee [Unilateral Symptomatic OA] [ Time Frame: Baseline and Week 52 ]
    Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Official Title  ICMJE A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Brief Summary The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis
Intervention  ICMJE
  • Drug: SM04690
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: 0.03 mg SM04690
    Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
    Intervention: Drug: SM04690
  • Experimental: 0.07 mg SM04690
    Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
    Intervention: Drug: SM04690
  • Experimental: 0.23 mg SM04690
    Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
    Intervention: Drug: SM04690
  • Placebo Comparator: Placebo
    Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
    Intervention: Drug: Placebo
Publications * Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-Like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 May 20. doi: 10.1002/art.41315. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 17, 2017)
455
Original Estimated Enrollment  ICMJE
 (submitted: August 28, 2015)
445
Actual Study Completion Date  ICMJE April 20, 2017
Actual Primary Completion Date April 20, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females between 40 and 80 years of age, inclusive, in general good health
  2. Ambulatory (single assistive devices such as canes allowed if needed less than 50% of the time, subjects requiring a walker are excluded)
  3. Established diagnosis of primary femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria for at least 6 months (clinical AND radiographic criteria); if bilateral knee OA is present, the target knee is defined as the knee with greater pain at screening based on the subject's evaluation and the Investigator's clinical judgment
  4. Radiographic disease Stage 2 or 3 in the target knee according to the Kellgren-Lawrence grading of knee OA as assessed by independent central readers
  5. Screening pain visual analog scale (VAS) score of 30-80 mm (on a scale of 0-100 mm) for the target knee while on symptomatic oral treatment at screening (if the subject requires oral treatment)
  6. Total WOMAC score of 72-192 (out of 240) for the target knee while on symptomatic oral treatment at screening (if the subject requires oral treatment)
  7. Willingness to omit the following for 24 hours prior to all Study Visits, excluding the Screening Visit:

    1. Pain medications
    2. Medications or supplements for the treatment of OA
    3. Participation in a formalized in-office and/or supervised OA disease program (e.g., a prescribed patient education program, physiotherapy, etc.)
  8. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
  9. Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed
  10. Subject's Day 1 visit must occur while enrollment into the study is open

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Women of childbearing potential (i.e., who are not surgically sterile or postmenopausal as defined by no menstrual periods for 12 consecutive months and no other biological or physiological cause for amenorrhea can be identified); males who are sexually active and have a partner who is capable of becoming pregnant, neither of which have had surgery to become sterilized, who are not using an effective method of birth control (e.g., surgically-implanted hormonal therapy, intrauterine devices or oral birth control with barrier method)
  3. Body mass index (BMI) >40
  4. Partial or complete joint replacement in the target knee
  5. Previous exposure to SM04690
  6. Major surgery (e.g., interventional arthroscopy) in the target knee within 52 weeks prior to any study injection
  7. Any planned or elective surgery during the study period
  8. Significant and clinically evident misalignment of the target knee that would impact subject function, as determined by the Investigator
  9. History of malignancy within the last 5 years; however, subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to any study injection
  10. Clinically significant abnormal Screening Visit hematology values, blood chemistry values, HbA1c, or urinalysis values as determined by the investigator
  11. Any condition, including laboratory findings (not included in the Screening Visit laboratory tests) and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  12. Comorbid conditions that could affect pain assessment of the target knee, including, but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, diabetic neuropathy, pseudogout, gout, and fibromyalgia
  13. Other conditions that, in the opinion of the Investigator, could affect pain assessment of the target knee, including, but not limited to, symptomatic hip osteoarthritis and symptomatic degenerative disc disease
  14. Any diagnosed psychiatric condition that includes, but is not limited to, a history of mania, bipolar disorder, psychotic disorder, schizophrenia, major depressive disorder, or generalized anxiety disorder
  15. Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 12 weeks prior to any study injection; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 12 weeks prior to Study Visit Day 1
  16. Treatment of the target knee with systemic or intra-articular corticosteroids (e.g., methylprednisolone) within 8 weeks prior to Study Visit Day 1
  17. Viscosupplementation (e.g., hyaluronic acid) in the target knee within 24 weeks prior to Study Visit Day 1
  18. Effusion of the target knee clinically requiring aspiration within 12 weeks prior to Study Visit Day 1
  19. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within 4 weeks prior to Study Visit Day 1
  20. Any known active infections, including suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV)
  21. Subjects taking prescription medications for OA who have not maintained a stable therapeutic regimen for a minimum of 12 weeks prior to Study Visit Day 1
  22. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks) of the medications listed below within 12 weeks prior to Study Visit Day 1:

    1. Opioids, both oral (e.g., tramadol) or transdermal (e.g., fentanyl patches) formulations
    2. Centrally acting analgesics (e.g., duloxetine)
    3. Glucocorticoids (e.g., methylprednisolone) administered by any route, with exception of inhaled, intranasal, and ophthalmic solutions
  23. Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy for a minimum of 12 weeks prior to Study Visit Day 1. In addition, the following subjects will be excluded:

    1. Subjects with a baseline HbA1c >9
    2. Subjects with uncontrolled hypertension in the opinion of the investigator
    3. Subjects with symptomatic coronary artery disease in the opinion of the investigator
  24. Subjects who have a current or pending disability claim, workers' compensation, or litigation(s) that may compromise response to treatment
  25. Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
  26. Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 40 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02536833
Other Study ID Numbers  ICMJE SM04690-OA-02
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Samumed LLC
Study Sponsor  ICMJE Samumed LLC
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Yusuf Yazici, M.D. Samumed LLC
PRS Account Samumed LLC
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP